Needham reiterates USD 98 target for Alcon stock after Neurotech deal

Published on 10/22/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon's Neurotech deal cost USD 550 million. Alcon stock costs EUR 60.67 on October 22, 2026, 0.51 percent above Xetra close.

Neurotech deal and earnings dates

Alcon paid USD 550 million for Neurotech Pharmaceuticals on October 20, 2026.
Second-quarter 2026 revenue reached USD 2.82 billion versus USD 2.77 billion consensus.
Alcon stock trades at EUR 60.67 at 9:42 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.51 percent above the Xetra close of October 21, 2026.
Needham reiterated a USD 98.00 price target on October 21, 2026.

Watercolor illustration of a stylized human eye centered in wide panoramic composition. Iris rendered in intricate pastel rainbow patterns in lavender, mint, peach, gold with delicate ink linework and translucent watercolor washes — Alcon CH0432492467: Aquarell Illustration eines Auges mit bunten Iris Mustern in zarten Pastellfarben, Illustration mit AI erstellt.

Alcon (ISIN CH0432492467) trades at EUR 60.67 at Lang & Schwarz on October 22, 2026 at 9:42 a.m. CEST, 0.51 percent above the Xetra close of October 21, 2026 at EUR 60.36. The latest catalyst is the company's USD 550 million acquisition of Neurotech Pharmaceuticals and its ENCELTO retinal therapy, announced on October 20, 2026, according to Business Wire.

Neurotech adds a retina asset

The transaction gives Alcon ENCELTO, the first U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2. Alcon said the deal should be modestly accretive to net sales growth and slightly dilutive to core diluted earnings per share in 2027, before becoming accretive thereafter, Business Wire reported.

The chronology shows a broader portfolio push. On October 16, 2026, Alcon received approval for BRYTLY, an over-the-counter redness-relief eye drop offering up to 12 hours of relief, according to FinanzNachrichten. On October 20, 2026, it acquired Neurotech for USD 550 million. On October 21, 2026, Needham reiterated its Buy rating and a USD 98.00 target, according to TradingView.

What does the deal mean for earnings?

The near-term earnings effect is the key investor question because Alcon expects slight core diluted earnings-per-share dilution in 2027. Its second-quarter 2026 revenue was USD 2.82 billion versus USD 2.77 billion consensus, a comparison reported by Earnings Today. That gives the Neurotech purchase a measurable test: commercialization must add growth beyond Alcon's existing operating base.

Next reporting date

Alcon's next scheduled event is its third-quarter 2026 earnings announcement on November 10, 2026, according to Yahoo Finance. That release should provide the next reported view of sales momentum before the 2027 dilution forecast can be tested.

Alcon stock stays near EUR 60

Alcon has a market capitalization of USD 32.6 billion as of October 21, 2026. Its U.S. listing closed at USD 67.43 on the Nasdaq on October 21, 2026 at 4:00 p.m. EDT, while the euro reference price is higher than the prior Xetra session close by EUR 0.31.

Alcon stock was trading at EUR 60.67 at Lang & Schwarz on October 22, 2026 at 9:42 a.m. CEST, 0.51 percent above the Xetra close of October 21, 2026 at EUR 60.36. The further course of trading is shown by the continuously updated real-time quote of Alcon stock.